Molecular Docking and Drug-Likeness Prediction of Flavonoid Compounds as COX-2 Inhibitors: An In Silico Study with Celecoxib Re-Docking Validation

Authors

  • Farhan Nur Huda Department of Nanotechnology Engineering, Faculty of Advanced Technology and Multidiscipline, Universitas Airlangga, Surabaya
  • Nabila Widya Artha Ramadhani Department of Nanotechnology Engineering, Faculty of Advanced Technology and Multidiscipline, Universitas Airlangga, Surabaya
  • Georgean Hugo Firmando Department of Nanotechnology Engineering, Faculty of Advanced Technology and Multidiscipline, Universitas Airlangga, Surabaya
  • Matthew Aric Christoper Alecia Department of Nanotechnology Engineering, Faculty of Advanced Technology and Multidiscipline, Universitas Airlangga, Surabaya
  • Jamie Fransisco Purba Department of Nanotechnology Engineering, Faculty of Advanced Technology and Multidiscipline, Universitas Airlangga, Surabaya
  • Wahyu Rama Iswara Department of Nanotechnology Engineering, Faculty of Advanced Technology and Multidiscipline, Universitas Airlangga, Surabaya
  • Mughni Ghatsa Pramudiwiyanto Department of Nanotechnology Engineering, Faculty of Advanced Technology and Multidiscipline, Universitas Airlangga, Surabaya
  • Noctorio Arry Athallah Department of Nanotechnology Engineering, Faculty of Advanced Technology and Multidiscipline, Universitas Airlangga, Surabaya
  • Muhammad Adriansyach Ramadhani Department of Nanotechnology Engineering, Faculty of Advanced Technology and Multidiscipline, Universitas Airlangga, Surabaya
  • Imam Siswanto Department of Chemistry, Faculty of Science and Technology, Universitas Airlangga, Surabaya

DOI:

https://doi.org/10.67096/medis.v1i2.317

Keywords:

molecular docking, drug-likeness, flavonoid, COX-2 inhibitor, in silico

Abstract

Long-term use of NSAIDs is associated with gastrointestinal and cardiovascular adverse effects. That persistent problem has pushed a lot of research toward natural molecules that reduce inflammation with fewer adverse effects. Flavonoids have garnered significant attention because many are active and safe, however, the precise mechanism by which flavonoids interact with cyclooxygenase‑2 (COX‑2) has not yet been fully elucidated through molecular docking. We selected six of them, quercetin, kaempferol, apigenin, myricetin, luteolin, and genistein, and docked each into the COX‑2 crystal structure (PDB ID: 3LN1) using UCSF DOCK6. Celecoxib was the reference. The co‑crystallized ligand was re‑docked first; the RMSD came out at 0.774 Å. That sits comfortably below the 2.40  Å acceptance limit, so the protocol was reliable for the rest of the work. Quercetin bound tightest: its Grid Score reached –36.36 kcal/mol, roughly 63.4% of the celecoxib score. Kaempferol (–36.25 kcal/mol) and apigenin (–34.69 kcal/mol) were close behind. Inside the active site, quercetin formed five hydrogen bonds, and additional Pi‑alkyl plus van der Waals contacts kept it firmly in place. When we checked drug‑likeness, all six flavonoids met Lipinski's rule of five except myricetin; its topological polar surface area hit 147.68 Ų, causing a single violation. Blood‑brain barrier penetration was estimated from PSA values. Quercetin, kaempferol, myricetin, and luteolin all have PSA above 90 Ų, so meaningful brain entry is unlikely, precisely what we would consider ideal for a peripheral anti‑inflammatory agent. Apigenin and genistein (PSA 86.99 Ų) sit right at the threshold. Quercetin and kaempferol stand out as the strongest leads for peripheral anti‑inflammatory therapy, and the next logical steps are in vitro COX‑2 inhibition assays followed by preclinical testing.

References

K. Megha, X. Joseph, V. Akhil, and P. Mohanan, "Cascade of immune mechanism and consequences of inflammatory disorders," Phytomedicine, vol. 91, p. 153712, 2021, doi: 10.1016/j.phymed.2021.153712.

Z. Ju, M. Li, J. Xu, D. C. Howell, Z. Li, and F.-E. Chen, "Recent development on COX-2 inhibitors as promising anti-inflammatory agents: The past 10 years," Acta Pharm. Sin. B, vol. 12, pp. 2790–2807, 2022, doi: 10.1016/j.apsb.2022.01.002.

N. Khalil, E. M. Ahmed, T. Tharwat, and Z. Mahmoud, "NSAIDs between past and present; a long journey towards an ideal COX-2 inhibitor lead," RSC Adv., vol. 14, pp. 30647–30661, 2024, doi: 10.1039/d4ra04686b.

M. Ahmadi, S. Bekeschus, K. Weltmann, T. Von Woedtke, and K. Wende, "Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors," RSC Med. Chem., vol. 13, pp. 471–496, 2022, doi: 10.1039/d1md00280e.

C. Stiller and P. Hjemdahl, "Lessons from 20 years with COX-2 inhibitors: Importance of dose-response considerations and fair play in comparative trials," J. Intern. Med., vol. 292, pp. 557–574, 2022, doi: 10.1111/joim.13505.

Y. L. Aguirre-García, A. Castillo-Manzanares, L. Palomo-Ligas, J. Ascacio-Valdés, L. Campos-Múzquiz, S. C. Esparza-González, R. Rodríguez-Herrera, and S. D. Nery-Flores, "Toxicity evaluation of a polyphenolic extract from Flourensia cernua DC through Artemia lethality assay, hemolytic activity, and acute oral test," Journal of Toxicology, vol. 2024, Art. no. 2970470, 2024, doi: 10.1155/2024/2970470.

T. A. Listyani, M. Addawiyyah, D. Raharjo, and P. J. Chyang, "Docking and Structural Modification of Flavonoid Derivative Compounds as Cyclooxygenase-2 Enzyme Inhibitors," Indonesian Journal of Global Health Research, vol. 7, no. 1, pp. 311–322, 2025, doi: 10.37287/ijghr.v7i1.4041.

A. H. El-Sayed, "Molecular docking and ADMET profiling of flavonoid derivatives as potential inhibitors of cyclooxygenase-2 enzyme," International Journal of Advanced Chemical Research, vol. 6, no. 1, pp. 160–164, 2024, doi: 10.33545/26646781.2024.v6.i1b.661.

S. Hossaini Alhashemi, F. Zare, S. Sadeghian, A. Poustforoost, and A. Dehshahri, “Identification of potential natural analgesic compounds through molecular docking-virtual screening, molecular dynamics simulation, MM/GBSA, DFT, and ADMET computations,” Sci. Rep., vol. 15, p. 39995, 2025, doi: 10.1038/s41598-025-23655-y.

B. Salehi et al., “Therapeutic Potential of Quercetin: New Insights and Perspectives for Human Health,” ACS Omega, vol. 5, no. 20, pp. 11849–11872, 2020, doi: 10.1021/acsomega.0c01818.

S. R. Kane et al., “In Silico Molecular Estimation of Flavonoid as A Cyclooxygenase-2 Inhibitor,” Revista Electronica De Veterinaria, vol. 25, no. 1S, pp. 823–825, 2024, doi: 10.69980/redvet.v25i1S.880.

Y. Li et al., “Quercetin, Inflammation and Immunity,” Nutrients, vol. 8, no. 3, p. 167, 2016, doi: 10.3390/nu8030167.

R. A. Putri, M. Y. Saputra, N. N. Enggelina, L. Windasari, and A. L. Ivansyah, “Potensi Antiinflamasi Senyawa Bioaktif dari Syzygium myrtifolium: Studi Molecular Docking Bertarget COX-2,” Jurnal Buana Farma, vol. 5, no. 2, pp. 214–222, 2025, doi: 10.36805/jbf.v5i2.1404.

P. Janakiramulu and E. Mamidala, “Molecular Docking and dynamic simulation analysis of flavonoid derivatives as COX-2 inhibitors,” In Silico Pharmacol., vol. 13, no. 2, p. 59, 2025, doi: 10.1007/s40203-025-00349-x.

A. Daina, O. Michielin, and V. Zoete, “SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules,” Sci. Rep., vol. 7, no. 1, Art. no. 42717, 2017, doi: 10.1038/srep42717.

L. Pinzi and G. Rastelli, “Molecular docking: shifting paradigms in drug discovery,” Int. J. Mol. Sci., vol. 20, no. 18, p. 4331, 2019, doi: 10.3390/ijms20184331.

Published

2026-06-28

How to Cite

Farhan Nur Huda, Nabila Widya Artha Ramadhani, Georgean Hugo Firmando, Matthew Aric Christoper Alecia, Jamie Fransisco Purba, Wahyu Rama Iswara, … Imam Siswanto. (2026). Molecular Docking and Drug-Likeness Prediction of Flavonoid Compounds as COX-2 Inhibitors: An In Silico Study with Celecoxib Re-Docking Validation. Medis: Jurnal Inovasi Kesehatan Dan Medika Nusantara, 1(2), 208–223. https://doi.org/10.67096/medis.v1i2.317